2023
Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up
Becerra L, Gavrieli A, Khan F, Novak P, Lioutas V, Ngo L, Novak V, Mantzoros C. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up. Clinical Nutrition 2023, 42: 825-834. PMID: 37084469, PMCID: PMC10330069, DOI: 10.1016/j.clnu.2023.04.008.Peer-Reviewed Original ResearchConceptsBody mass indexType 2 diabetesIntranasal insulinSecondary outcomesFood intakeBody compositionType 2 diabetes trialsOlder adultsPlacebo-controlled studyPlacebo-controlled trialDiabetes (ACCORD) trialPrimary outcomeIntervention visitsMass indexBody fatAnthropometric measuresAnimal studiesBody weightHigh dosesInteraction of treatmentEnergy homeostasisDiabetesInsulinWeight lossAppetite
2022
Depressive symptoms exacerbate disability in older adults: A prospective cohort analysis of participants in the MemAID trial
Buss S, Becerra L, Trevino J, Fortier C, Ngo L, Novak V. Depressive symptoms exacerbate disability in older adults: A prospective cohort analysis of participants in the MemAID trial. PLOS ONE 2022, 17: e0278319. PMID: 36445876, PMCID: PMC9707770, DOI: 10.1371/journal.pone.0278319.Peer-Reviewed Original ResearchConceptsDepressive symptomsImportant modifiable risk factorOlder adultsWeek 48 visitModifiable risk factorsProspective cohort analysisEffect of comorbiditySelf-reported disabilityType 2 diabetesGeriatric Depression ScalePublic health priorityIntranasal insulinMedical comorbiditiesCardiovascular mortalityGait speedRisk factorsClinical trialsNormal limitsWeek 25Depression ScaleHealth priorityCohort analysisComorbiditiesWorse cognitionCognitive declineMemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial
Novak V, Mantzoros C, Novak P, McGlinchey R, Dai W, Lioutas V, Buss S, Fortier C, Khan F, Aponte Becerra L, Ngo L. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. Journal Of Neurology 2022, 269: 4817-4835. PMID: 35482079, PMCID: PMC9046533, DOI: 10.1007/s00415-022-11119-6.Peer-Reviewed Original ResearchConceptsIntranasal insulinCerebral blood flowPlasma insulinBlood flowType 2 diabetes mellitusVerbal memorySerious adverse eventsDouble-blinded trialRandomized clinical trialsType 2 diabetesAge-related functional declineHOMA-IRAdverse eventsDiabetes mellitusPrimary outcomeWeeks treatmentHypoglycemic episodesT2DM participantsControl placeboPreliminary safetyClinical trialsFunctional declineLong-term effectsBackgroundThis studyBetter executive function